Stockscreener 앱 받기
0.85
2.62%
-0.0229
시간 외 거래:
.84
-0.01
-1.18%
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Biotech Inc.Common Stock (NQ: ONCY - FinancialContent
Oncolytics Biotech stock (CA6823101073): Q1 loss deepens and going concern warning puts focus on cas - AD HOC NEWS
Oncolytics Biotech (ONCY) doubles Q1 loss and warns on going concern - Stock Titan
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
Oncolytics Biotech stock (CA6823101073): Q4 earnings miss and upcoming report - AD HOC NEWS
TradingKey - TradingKey
Oncolytics Biotech (ONCY) Eps Diluted (TTM) - Zacks Investment Research
Lobbying Update: $35,000 of ONCOLYTICS BIOTECH INC. lobbying was just disclosed - Quiver Quantitative
ONCY: Oncolytics BiotechInteractive Chart - Zacks Investment Research
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks - MSN
Oncolytics Biotech’s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook - Sahm
Oncolytics Biotech Reports Data in Colorectal Cancer Study - IPO Edge
Oncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum - Quantisnow
Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer, Pursues Accelerated FDA Approval for Pelareorep Therapy 7 - Minichart
Oncolytics Says Colorectal Cancer Drug Outperforms BenchmarksOncolytics Biotech (NASDAQ:ONCY) - Benzinga
Stocks In Play - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart
Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC - TradingView
Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer - TradingView
A colorectal cancer study hit 19.5-month response duration as FDA talks start - Stock Titan
Durable mCRC responses spur FDA talks for Oncolytics Biotech (NASDAQ: ONCY) - Stock Titan
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer - Yahoo Finance
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech - Zacks Small Cap Research
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY) and Agilon Health (AGL) - The Globe and Mail
Lake Street Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oncolytics aligns with FDA on pivotal trial design for anal cancer By Investing.com - Investing.com South Africa
Oncolytics aligns with FDA on pivotal trial design for anal cancer - Investing.com UK
Oncolytics Biotech Aligns With FDA on Study Design for Pelareorep in Anal Cancer - marketscreener.com
Oncolytics (ONCY) Secures FDA Agreement on Pivotal Study Design - GuruFocus
Oncolytics Biotech Inc announces alignment with FDA on pivotal anal cancer study - marketscreener.com
Oncolytics Biotech Aligns with FDA on Pelareorep Trial - TipRanks
Oncolytics Biotech Aligns with FDA on Pivotal Study for Anal Cancer Immunotherapy Approval - Minichart
Oncolytics surges on FDA alignment for pivotal cancer trial By Investing.com - Investing.com India
Oncolytics Biotech | 8-K: Current report - Moomoo
Oncolytics surges on FDA alignment for pivotal cancer trial - Investing.com
Oncolytics aligns with FDA on randomized pivotal anal cancer trial for pelareorep - TradingView
Oncolytics Biotech (Nasdaq: ONCY) secures FDA alignment on pivotal anal cancer study design - Stock Titan
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study - ChartMill
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths (NASDAQ:ONCY) - Seeking Alpha
ONCY (Oncolytics Biotech Inc. Common Shares) posts wider Q3 2025 loss than consensus estimates, shares rise 5.66 percent.Social Investment Platform - Xã Thanh Hà
ONCY Should I Buy - Intellectia AI
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst - MarketBeat
Published on: 2026-04-14 02:49:57 - baoquankhu1.vn
Equities Analysts Issue Forecasts for ONCY Q1 Earnings - MarketBeat
0.71%
자본화:
|
볼륨(24시간):